HUB Investment Partners LLC Sells 4,682 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

HUB Investment Partners LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 64.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,636 shares of the biopharmaceutical company's stock after selling 4,682 shares during the quarter. HUB Investment Partners LLC's holdings in Gilead Sciences were worth $244,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC grew its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 1.7 %

GILD stock traded up $1.89 during midday trading on Thursday, reaching $111.16. The company's stock had a trading volume of 6,382,732 shares, compared to its average volume of 6,810,437. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a market capitalization of $138.43 billion, a price-to-earnings ratio of 300.43, a PEG ratio of 0.71 and a beta of 0.21. The stock has a fifty day simple moving average of $104.69 and a two-hundred day simple moving average of $94.46. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.84%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GILD shares. The Goldman Sachs Group upped their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.